As an adjuvant therapy, co-administration of HSP90 inhibitor, NVP-AUY922, with ABT-737, BCL-2 inhibitor, enhances the anti-cancer effect of ABT-737 by targeting MCL-1 protein that grants the cancer resistance to ABT-737 in small cell lung cancer [195]. This evidence concerns the gene BCL2 and cancer.